Plaintiffs to appeal after court dismisses lawsuit against IRadimed

Michael Walter | | Radiology Business | Economics

The plaintiffs in a class action lawsuit against IRadimed Corporation, a Winter Springs, Fla.-based developer and manufacturer of MRI-related products, have filed a notice of appeal after the case was dismissed back in May. IRadimed announced the news in a statement, saying it “intends to continue to vigorously defend against plaintiff’s claims.”

Shareholders filed the lawsuit because, they said, IRadimed allegedly failed to disclose certain information about the company’s compliance with Food and Drug Administration regulations. IRadimed disputed the allegation.

When the U.S. District Court for the Southern District of Florida first dismissed the case, Roger Susi, IRadimed’s president and CEO, said in a statement that the company was ready to move forward.

“We are pleased with this ruling and will continue to focus on meeting the needs of our customers,” Susi said at the time.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers
Congress ditches doc fix in stopgap end-of-year funding bill
Teleradiology provider inks post-acute care deal worth $1.5M annually
US Radiology Specialists affiliate expands into new market
Radiologist rails against insurer’s refusal to cover key interventional service
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.